Advances in Angiogenesis, Inflammation, and Oxidative Stress in Inflammatory Bowel Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 15 January 2025 | Viewed by 642

Special Issue Editors


E-Mail Website
Guest Editor
Department of Immunology, University of Medicine and Pharmacy, 200349 Craiova, Romania
Interests: pancreatic disorders; polymorphism; genotype; VEGFR-2; vitamin C; ascorbic acid; diabetes mellitus; periodontal disease; antigens; monoclonal antibody; NLRP3; citokines; pro-angiogenic factors; chronic periodontitis; case-control; matrix metalloproteinase; periodontal parameters
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Gastroenterology, University of Medicine and Pharmacy of Craiova, Craiova, Romania
Interests: inflammatory bowel diseases; digestive cancers; endoscopic imaging

Special Issue Information

Dear Colleagues,

Research over the last few decades has led to the use of biological therapy with human monoclonal antibodies, which has enabled the improved regulation of both the cellular immune response and inflammation of the intestinal mucosa, leading to clinical remission and endoscopic healing. However, there are patients in whom mucosal healing is not observed or alters the natural history of their inflammatory bowel disease.

In light of these observations, in this Special Issue, we will collect important studies (original research or review articles) regarding the evaluation of angiogenic, inflammatory, and oxidative stress in patients with IBD.

Studies investigating the hypothesis that angiogenesis and oxidative stress contribute significantly to mucosal inflammation in IBD are also welcome. Since symptoms are often subjective, and invasive procedures are often a burden for the patient, studying the interrelation between angiogenic factors, inflammatory markers, and oxidative stress factors will enable an objective measurement of disease activity.

Dr. Mihail Virgil Boldeanu
Prof. Dr. Dan Ionuț Gheonea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory bowel disease
  • angiogenesis
  • inflammation
  • oxidative stress

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1822 KiB  
Article
Spasmolytic Activity of 1,3-Disubstituted 3,4-Dihydroisoquinolines
by Miglena Milusheva, Mihaela Stoyanova, Vera Gledacheva, Iliyana Stefanova, Mina Todorova and Stoyanka Nikolova
Biomedicines 2024, 12(7), 1556; https://doi.org/10.3390/biomedicines12071556 - 13 Jul 2024
Viewed by 277
Abstract
This article concerns the spasmolytic activities of some novel 1,3-disubstituted 3,4-dihydroisoquinolines. These compounds can be evaluated as potential therapeutic candidates according to Lipinski’s rule of five, showing high gastrointestinal absorption and the ability to cross the blood–brain barrier, which is a very important [...] Read more.
This article concerns the spasmolytic activities of some novel 1,3-disubstituted 3,4-dihydroisoquinolines. These compounds can be evaluated as potential therapeutic candidates according to Lipinski’s rule of five, showing high gastrointestinal absorption and the ability to cross the blood–brain barrier, which is a very important parameter in the drug discovery processes. In silico simulation predicted smooth muscle relaxant activity for all the compounds. Since smooth muscle contractile failure is a characteristic feature of many disorders, in the current paper, we concentrate on the parameters of the spontaneous contractile responses of smooth muscle (SM) cells compared to the well-known drug mebeverine. Two of the newly synthesized substances can be identified as essential modulating regulators and potentially used as therapeutic molecules. One of these molecules also showed significant DPPH antioxidant activity compared to rutin. Full article
Show Figures

Figure 1

Back to TopTop